Health Trials

DLL3-expressing Tumors

2

Review clinical trials related to DLL3-expressing Tumors. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.

Participants needed: 29
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jonsson Comprehensive Cancer CenterUpdated: May 18, 2026Locations: 5
Eligibility criteria

Participant has provided informed consent prior to initiation of any study speci... [+12]

Diagnosis of SCLC (with the exception of SCLC transformed from previously-treate... [+33]

Read more
Status: Recruiting

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.

Participants needed: 60
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Xiamen UniversityUpdated: Mar 9, 2026Locations: 1
Eligibility criteria

Adult patients (aged 18 years or older); [+4]

The inability or unwillingness of the research participant or legal representati... [+1]

Read more